TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02961855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anesthesics plus antiinflammatory, CLIFE1
Description: anesthesics plus antiinflammatory, CLIFE1 topical gel containing lidocaine plus diclofenac anesthesics plus antiinflammatory

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesics, CLIFE2
Description: local anesthesics, CLIFE2 topical gel containing lidocaine local anesthesics
Study: NCT02774265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VTE prophylaxis with Enoxaparin 30mg BID
Description: Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VTE prophylaxis with Aspirin 81mg BID
Description: Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
Study: NCT02291224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive multimedia platform
Description: An interactive platform that includes video vignettes of young women who are choosing dual protection strategies (based on a synthesis of focus group data from members of the TSC patient population), as well as true/false questions to build knowledge about dual protection and dispel common myths about contraceptive strategies. There will also be reflection questions that encourage participants to consider values and priorities in their own lives that may influence their dual protection strategy selection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention arm counseling
Description: Counseling for the intervention group will follow carefully developed guides and incorporate the participants' answers to the reflection questions in the interactive multi-media component. This counseling has a set structure (set forth in separate counseling guides for health care providers and nurse educators), incorporates motivational interviewing techniques, includes multiple opportunities for role play, and is designed to be patient-centered.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of care counseling
Description: Standard of care counseling is provided by health care providers and health educators at TSC. It incorporates extensive counseling on methods to prevent both unintended pregnancy and sexually transmitted infections, however the structure of the counseling and techniques used are dependent on the standard practice of each provider or educator. This counseling does not incorporate answers to reflection questions from the multi-media platform because control arm participants will not view this content.
Study: NCT01597115

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duplex ultrasonography
Study: NCT03726554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comprehensive Reverse Porous Augmented Glenoid
Description: Three glenoid baseplate options designed for various severities of glenoid erosion and deformity, the device promotes bony ingrowth while restoring natural human anatomy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comprehensive Mini Humeral Tray
Description: The mini humeral tray offers additional sizing options to the Comprehensive Shoulder line. The mini tray is designed to fit smaller anatomies.
Study: NCT00935155

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Westerns style acupuncture. Twice a week for 12 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: Coordination, mobilizing, endurance, strength
Study: NCT04151108

Intervention type: OTHER
Intervention: Development of a risk assessment tool for loss of muscle mass and physical function based on clinical and functional measures and systemic biomarkers
Description: Blood tests, frailty (CSHA Clinical Frailty Scale), Early Warning Score (EWS), cognitive status, sarcopenia (SARC-f), malnutrition (SNAQ), comorbidity (Charlson comorbidity Index), polypharmacy, physical function, physical performance, and body composition (BIA)
Study: NCT02890719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg/day
Description: Grazoprevir 100 mg/ day 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg/d
Description: Elbasvir 50 mg/day 12 weeks
Study: NCT03354793

Intervention type: OTHER
Intervention: Survey on first pregnancy after endometriosis diagnosis
Description: Obstetric complications were noted

Intervention type: OTHER
Intervention: Survey on first pregnancy
Description: Obstetric complications were noted
Study: NCT01903252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP05
Description: 3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asacol 400 mg
Description: 3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)
Study: NCT00124839

Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone
Description: Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone

Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone
Description: Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone

Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone
Description: Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone

Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone
Description: Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone
Study: NCT03033433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCB-DM101
Description: determination of optimal dose for Stage 2
Study: NCT02726399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab 8mg/kg administered intravenously on days 1 and 8 ever 21 days
Study: NCT02890719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg/day
Description: Grazoprevir 100 mg/day 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg/day
Description: Elbasvir 50 mg/d 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin 1200 mg/day
Description: Ribavirin 1200 mg/day 16 weeks
Study: NCT02832089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral carvedilol
Description: oral carvedilol in escalating doses for reducing ventricular rate in AF patients
Study: NCT02207907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate plus sodium fluoride
Description: Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride
Description: Toothpaste containing 1100 ppm fluoride as sodium fluoride
Study: NCT00215930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Ribonucleotide reductase subunit 1(RRM1)above 16.5 and Excision repair cross-complementing group 1 gene(ERCC1)above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve \[AUC\] of 5 on day 1) every 21 days.~RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve \[AUC\] of 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.
Study: NCT02844790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: A single dose of IDegAsp will be administered subcutaneously (s.c., under the skin).
Study: NCT03415165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: green tea buccal tablet
Description: buccal tablet for 8 hrs 3 times aday

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Corticosteroids Topical
Description: kenacort in orabase 4 times aday
Study: NCT01079767

Intervention type: DRUG
Group type: OTHER
Intervention: temsirolimus
Study: NCT00850252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lifeline
Description: Surgical arteriovenous fistula formation with the use of Lifeline blood vessel
Study: NCT02215759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 TA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02815215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Carroll's Technique
Description: Patient will be treated with minimally invasive Carroll's technique by 3 small incisions in the heel, in the medial side of the foot and in the planta pedis, respectively. Long-leg plaster cast fixation was applied for 6-8 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ponseti method
Description: As a control, Patient will be treated with classical Ponseti method, including multiple steps: manipulative correction, continuous plaster, achilles tendon cutting, fixation.
Study: NCT03386084

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: microwave diathermy
Description: Application of microwave diathermy with Monopolar CapacitiveResistive Radiofrequency Therapy (INDIBA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microwave diathermy
Description: Application of microwave diathermy with Monopolar CapacitiveResistive Radiofrequency Therapy (INDIBA)
Study: NCT01865292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
Study: NCT02585557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Care Practice Support
Description: The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Care Practice Support
Description: The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Care Practice Support
Description: The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Care Practice Support
Description: The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Care Practice Support
Description: The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
Study: NCT02440750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: operative hysteroscopy
Description: Performed under general or local anesthesia, antibioprophylaxis may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: operative hysteroscopy
Description: Performed under general or local anesthesia, antibioprophylaxis may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest
Description: 21 days administration of dienogest 2 mg/die

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate
Description: 21 days administration of ulipristal acetate 5 mg/die
Study: NCT02589977

Intervention type: DRUG
Group type: OTHER
Intervention: regadenoson
Description: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants

Intervention type: DRUG
Group type: OTHER
Intervention: regadenoson
Description: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants

Intervention type: DRUG
Group type: OTHER
Intervention: regadenoson
Description: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants
Study: NCT01106924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: daily probiotic consumption
Study: NCT04652089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg
Description: Simvastatin 20mg once a day for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once a day for 7 days
Study: NCT01136954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Transition Period from Study E2090-E044-312: Placebo Open-Label Period: 1 to 8 mg/kg orally per day for approximately 59 weeks.
Study: NCT03478280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brodalumab
Description: Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
Study: NCT04013464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10-20mg/d
Study: NCT02661724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TCBR-Pain
Description: The interactive TCBR-Pain uses programmed learning, skill development and behavioral practice to engage persons with burn pain in self-management of pain and related problems. The TCB-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress. The lessons are narrated and include closed captioning, are animated, and include branching to provide personalized content.
Study: NCT04129541

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Same Day Discharge
Description: Patients in the planned same day discharge (SDD) cohort will be discharged from the PACU once they meet standard discharge criteria.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overnight Hospitalization
Description: Patients in the planned overnight hospitalization (OH) group will be discharged on post-operative day 1 once they meet standard discharge criteria.
Study: NCT01106924

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily placebo consumption
Study: NCT01025635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid foam 15%
Description: Applied topically twice daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam
Description: Applied topically twice daily for 12 weeks
Study: NCT00663247

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: 3 grams daily for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 grams daily for 3 months
Study: NCT00459056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol CR + Lisinopril
Description: Participants were given Carvedilol CR + Lisinopril for three months. Oral medication. Carvedilol CR and Lisinopril combination therapy was initiated at 20 mg and 10 mg, respectively. Patients returned one week later and doses of carvedilol CR and lisinopril were increased to 40 mg and 20 mg, respectively, depending on blood pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol CR + Lisinopril
Description: Participants were given Carvedilol CR + Lisinopril for three months. Oral medication. Carvedilol CR and Lisinopril combination therapy was initiated at 20 mg and 10 mg, respectively. Patients returned one week later and doses of carvedilol CR and lisinopril were increased to 40 mg and 20 mg, respectively, depending on blood pressure.
Study: NCT02553837

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hantavax injection
Description: A single 0.5mL dose intramuscular or subcutaneous injection
Study: NCT03406533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam is used as a common medication for sedation in all groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam is used as a common medication for sedation in all groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam is used as a common medication for sedation in all groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam is used as a common medication for sedation in all groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
Study: NCT03552744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailed training intervention
Description: PCPs from the intervention group will be mailed an intervention package that includes:~1. 2-page structured evidence summary on CRC screening and information about Colonoscopy \& FIT (Decision box)~2. patient decision aid (20-page booklet) on CRC screening for distribution to patients (Decision Aid)~3. video example for the PCP, which illustrates a participatory approach to discussing CRC screening with a patient~4. 4-page abridged version of the booklet to support PCPs when they discuss CRC screening with patients during a clinical visit (Decision Board)~5. individualized 1-page summary of PCP screening practices comparing their individual prescription patterns to group patterns, based on the data collected in 2017 (Performance card)~6. 2-page document that encourages PCPs still using the inferior guaiac-based FOBT to switch to FIT and includes list of laboratories from which they can order FIT~7. sample FIT for PCPs who may not be familiar with its contents and use
Study: NCT03514420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKCEA-ANGPTL3-LRx
Description: AKCEA-ANGPTL3-LRx solution for SC injection.
Study: NCT00459056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril + HCTZ
Description: Participants were given Lisinopril + HCTZ for three months. Oral medication. Lisinopril + HCTZ combination therapy was initiated at 12.5 mg and 10 mg, respectively. Patients returned 1 week later and doses of hydrochlorothiazide and lisinopril were increased to 25 mg and 20 mg, respectively, depending on blood pressure levels.
Study: NCT03406533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil is used for analgesia to prevent bronchoscopy induced cough.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.